Omeicos Therapeutics GmbH   Report issue

For profit Phase 2
Founded: Berlin Germany (2013)

Organization Overview

First Clinical Trial
2017
NCT03078738
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Managing Director | Omeicos Therapeutics GmbH

Active Ingredients

Drugs in Phase 2 Trials (1)

omt-28 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1